/Investor DB

Formulate Ventures — 2022 Investments

2 investments dated 2022 · listed companies and verified rows first · show all

Shennon Biotechnologiesshennonbio.cominDec 2022

ShennonBio develops immunotherapy technologies using microfluidic engineering, computational biology, and immunology to advance T cell engineering for cancer treatment.

AI & Machine LearningBiotechDeep TechMedical DevicesSan Francisco, US

Li Sun, PhD(Founder/CEO)in

BoardJAMES HARDIMAN(Director)in

Co-investorsAV8 VenturesDCVC (Data Collective)Foundation CapitalFuture VenturesNextGen Venture PartnersSamos Investments

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Graft

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.